5-ethyl-4-iodomethyl-2-(4-trifluoromethyl-phenyl)-oxazole | 876587-03-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-ethyl-4-iodomethyl-2-(4-trifluoromethyl-phenyl)-oxazole
• 英文别名: 5-Ethyl-4-iodomethyl-2-(4-trifluoromethylphenyl)oxazole；5-ethyl-4-(iodomethyl)-2-[4-(trifluoromethyl)phenyl]-1,3-oxazole
• CAS: 876587-03-0
• 化学式: C₁₃H₁₁F₃INO
• 分子量: 381.136
• InChiKey: NAAYFNGDSPPEQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-ethyl-4-iodomethyl-2-(4-trifluoromethyl-phenyl)-oxazole 在 sodium hydride 作用下， 以 甲基叔丁基醚 为溶剂， 生成 2-{(1S,3R)-3-[5-ethyl-2-(4-trifluoromethylphenyl)-oxazol-4-ylmethoxymethyl]-cyclohexylmethoxy}-2-methylpropionic acid tert-butyl ester
  参考文献：
  名称：

  [DE] 2-{-3-`2-(PHENYL)-OXAZOL-4-YLMETHOXY!- CYCLOHEXYLMETHOXY}-PROPIONSÄURE DERIVATE ALS PPAR-LIGANDEN (PEROXISOMEN-PROLIFERATOREN-AKTIVIERTE REZEPTOREN) ZUR BEHANDLUNG VON HYPERLIPIDÄMIE UND DIABETES
  [EN] 2 - { - 3 2 - (PHENYL)-OXAZOL-4-YLMETHOXYL-CYCLOHEXYLMETHOXY}-PROPIONIC ACID DERIVATIVES USED AS PPAR LIGANDES (PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS) FOR THE TREATMENT OF HYPERLIPIDAEMIE AND DIABETES
  [FR] DERIVES D'ACIDE 2-{-3- 2-(PHENYL)-OXAZOL-4-YLMETHOXYMETHYL-CYCLOHEXYLMETHOXY}-PROPIONIQUE UTILISES EN TANT QUE LIGANDS DES PPAR (RECEPTEURS ACTIVES PAR LES PROLIFERATEURS DE PEROXISOMES) POUR TRAITER L'HYPERLIPIDEMIE ET LE DIABETE

  摘要：

  该发明涉及式(I)的化合物，其中R代表H，CF3；R1代表H，CF3，(C1-C6)-烷基；苯基，苯氧基；R2代表H，(C1-C4)-烷基，O-(C1-C4)-烷基，CF3；或者R1和R2与苯环结合形成的萘基；R3代表(C1-C6)-烷基；R4代表(C1-C6)-烷基，苄基；R5代表H，(C1-C6)-烷基；以及它们的生理相容盐，溶剂化合物和生理功能衍生物。这些化合物可用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用障碍以及胰岛素抵抗相关的疾病。

  公开号：

  WO2006018118A1

文献信息

• Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040198786A1

  公开（公告）日：2004-10-07

  Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals The invention relates to cycloalkyl derivatives having bioisosteric carboxylic acid groups and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula 1, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistence is involved.

  环烷基衍生物具有生物等效羧酸基团，其制备方法及其作为药物的用途。本发明涉及具有生物等效羧酸基团的环烷基衍生物及其生理上可接受的盐和生理功能衍生物。所描述的化合物具有下式1,1中所定义的基团，以及它们的生理上可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用障碍以及胰岛素抵抗相关的紊乱。
• 2-{-3-'2-(PHENYL)-OXAZOL-4-YLMETHOXYMETHYL-CYCLOHEXYLMETHOXY}-PROPIONIC ACID DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES
  申请人：Glombik Heiner

  公开号：US20070197612A1

  公开（公告）日：2007-08-23

  The present invention comprises compounds and compositions for the treatment of metabolic disorders and more particularly, those insulin-related metabolic disorders of the blood such as hyperlipidemia, diabetes, insulin-resistence and the like comprising acetic acid derivatives with cyclohexylmethoxy substituents and their salts. Known as peroxisome proliferator-activated receptors (PPAR) agonists/antagonists, the invention relates to compounds of the formula I wherein the various substituent R-groups are more specifically defined herein.

  本发明涉及一种用于治疗代谢紊乱的化合物和组合物，特别是治疗与胰岛素有关的血液代谢紊乱，如高脂血症、糖尿病、胰岛素抵抗等的乙酸衍生物与环己基甲氧基取代基及其盐。该发明涉及配体激动剂/拮抗剂的过氧化物体增殖物激活受体（PPAR）的化合物，其化学式I中的各种取代基R组在此更具体地定义。
• Cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：Stapper Christian

  公开号：US20050215596A1

  公开（公告）日：2005-09-29

  Provided herein are cycloalkyl-substituted amino acid derivatives, processes for their preparation and their use as pharmaceuticals

  本文提供了环烷基取代的氨基酸衍生物，其制备过程以及作为药物的用途。
• 2-{-3-′2-(phenyl)-oxazol-4-ylmethoxymethyl-cyclohexylmethoxy}-propionic acid derivatives useful as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：US07538131B2

  公开（公告）日：2009-05-26

  The present invention comprises compounds and compositions for the treatment of metabolic disorders and more particularly, those insulin-related metabolic disorders of the blood such as hyperlipidemia, diabetes, insulin-resistance and the like comprising acetic acid derivatives with cyclohexylmethoxy substituents and their salts. Known as peroxisome proliferator-activated receptors (PPAR) agonists/antagonists, the invention relates to compounds of the formula I wherein the various substituent R-groups are more specifically defined herein.

  本发明涉及一种用于治疗代谢性疾病的化合物和组合物，尤其是治疗血液中胰岛素相关代谢紊乱（如高脂血症、糖尿病、胰岛素抵抗等）的乙酸衍生物和其盐，这些化合物被称为过氧化物酶体增殖物激活受体（PPAR）激动剂/拮抗剂，本发明涉及式I的化合物，其中各个取代基R组在此更具体地定义。
• 3-METHYL-2- (3- (2-PHENYL-OXAZOL-4-YLMETHOXY)-CYCLOHEXANCARBONYL-AMINO)-BUTTERSÄUREDERIVATE UND VERWANDTE VERBINDUNGEN ALS PPAR MODULATOREN ZUR BEHANDLUNG VON TYP 2 DIABETES UND ATHEROSKLEROSE
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1599453B1

  公开（公告）日：2009-05-06